“Wilms Tumor Protein 1”(WT1) peptide vaccination-induced complete remission in a patient with acute myeloid leukemia is accompanied by the emergence of a …
S Ochsenreither, A Fusi, A Busse, S Bauer… - Journal of …, 2011 - journals.lww.com
Within the last few years, the first peptide vaccination trials for treatment of acute myeloid
leukemia (AML) have been initiated. Athough the presence of epitope-specific T cells could
be seen both in bone marrow (BM) and peripheral blood (PB), nothing is known about their
clonal composition. In this study, we analyzed material from a patient with recurrent AML
vaccinated with “Wilms Tumor Protein 1”(WT1) peptide, who achieved a complete remission
(CR) lasting for 12 months. For identification of expanded WT1-specific T-cell clones …
leukemia (AML) have been initiated. Athough the presence of epitope-specific T cells could
be seen both in bone marrow (BM) and peripheral blood (PB), nothing is known about their
clonal composition. In this study, we analyzed material from a patient with recurrent AML
vaccinated with “Wilms Tumor Protein 1”(WT1) peptide, who achieved a complete remission
(CR) lasting for 12 months. For identification of expanded WT1-specific T-cell clones …